Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addex appoints Dr Bharatt Chowrira CEO

This article was originally published in Scrip

Executive Summary

Addex Pharmaceuticals has appointed Dr Bharatt Chowrira CEO, and dissolved the transition committee led by recently appointed vice-chairman Vincent Lawton, which was set up as an interim measure following the unexpected departure of former CEO Dr Vincent Mutel in June 2011 (scripintelligence.com, 3 June 2011). Dr Chowrira joins Addex from Nektar Therapeutics where he served as senior vice-president and COO, and he was previously executive director of worldwide licensing & external research at Merck & Co.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel